Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DX72LV
|
|||
Drug Name |
AZD4604
|
|||
Synonyms |
JAK1-IN-7; AZD4604; 2241039-81-4; AZD-4604; JAC34RRR7S; (2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; londamocitinib; UNII-JAC34RRR7S; CHEMBL4447181; SCHEMBL20399395; GTPL11716; BDBM488779; EX-A5343; US10961228, Example 35; AKOS040733485; AT39356; example 35 [WO2018134213A1]; MS-30607; HY-126294; CS-0101485; (R)-N-(3-(5-fluoro-2- (2-fluoro-3- (methylsulfonyl)phenyl amino)pyrimidin-4-yl)- 1H-indol-7-yl)-3- methoxy-2-(4- methylpiperazin-1- yl)propanamide; 1-Piperazineacetamide, N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha-(methoxymethyl)-4-methyl-, (alphaR)-
Click to Show/Hide
|
|||
Drug Type |
Small molecule
|
|||
Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 1 | [1] | |
Company |
AstraZeneca
|
|||
Structure |
Download2D MOL |
|||
Formula |
C28H31F2N7O4S
|
|||
Canonical SMILES |
CN1CCN(CC1)C(COC)C(=O)NC2=CC=CC3=C2NC=C3C4=NC(=NC=C4F)NC5=C(C(=CC=C5)S(=O)(=O)C)F
|
|||
InChI |
InChI=1S/C28H31F2N7O4S/c1-36-10-12-37(13-11-36)22(16-41-2)27(38)33-21-8-4-6-17-18(14-31-26(17)21)25-19(29)15-32-28(35-25)34-20-7-5-9-23(24(20)30)42(3,39)40/h4-9,14-15,22,31H,10-13,16H2,1-3H3,(H,33,38)(H,32,34,35)/t22-/m1/s1
|
|||
InChIKey |
JNUZADQZHYFJGW-JOCHJYFZSA-N
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04769869) A Single-blind, Randomized, Placebo-controlled 3 Part Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 Following Single and Multiple Ascending Doses and to Investigate the Anti-inflammatory Effect of Inhaled AZD4604. U.S.National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of AstraZeneca |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.